Biomarker

A non-invasive diagnostic model, based partially on saliva samples, distinguished between patients with and without Sjögren’s disease with high sensitivity and specificity, according to data published in Arthritis Research & Therapy.

Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests should only be ordered if the results will directly impact care, like when determining treatment eligibility.

Placental growth factor, a blood-based protein, may be a reliable method to detect abnormalities in the brain that presage cognitive impairment indicative of Alzheimer’s disease, data show.

Healio Neurology looks back at the most popular Q&As with industry and specialty experts from the past year.

INDIANAPOLIS — While it is known that choriocapillaris flow deficits can be a biomarker for diabetes, recent data presented at Academy 2024 indicated that prediabetic patients have lower flow deficit.

A Phoenix-area medical technology company has received $4.2M grant fromThe Michael J. Fox Foundation for Parkinson’s Research to support a study for a skin test that quantifies abnormal alpha-synuclein in those with Parkinson’s disease.

The ability of an artificial neural network to predict COPD exacerbations from urine samples was “excellent,” according to results published in ERJ Open Research.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, offers advice to new residents seeing patients with EGFR-mutated lung cancer.

In this video, J. Nicholas Bodor, MD, PhD, MPH, assistant professor in the department of hematology/oncology at Fox Chase Cancer, highlights important takeaways for interventional pulmonologists and other providers who may see patients with EGFR-mutated lung cancer.

In this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the 2024 World Conference on Lung Cancer, as well as Healio’s top headlines from the meeting.